11-61 28 Below
4.3 절 참고 문헌
[4.1] Straume T and Carsten AL, Tritium radiobiology and relative biological effectiveness.
Health Physics
65(6): 657-72, 1993.[4.2] Health Protection Agency (HPA), Review of risks from tritium with particular attention to tritiated water and organic compounds containing tritium. Report of AGIR subgroup on tritium risks, UK advisory group on ionizing radiation. 2007.
[4.3] Canadian Nuclear Safety Commission, Health Effects, Dosimetry and Radiological Protection of Tritium (INFO-0799), 2010,
[4.4] Little MP and Lambert BE, Systematic review of experimental studies of relative biological effectiveness of tritium.
Radiation and Environmental Biophysics
47(1): 71-93, 2008.[4.5] Trabalka JR and Kocher DC, Energy dependence of dose and dose-rate effectiveness factor for low-let radiations: Potential importance to estimation of cancer risks and relationship to biological effectiveness.
Health Physics
93(1): 17-27, 2007.[4.6] Hill MA, The variation of biological effectiveness of X-rays and gamma rays with energy.
Radiation Protection Dosimetry
112:471-481, 2004.
[4.7] International Commission on Radiation Units and Measurements (ICRU), Linear Energy Transfer. ICRU Report 16, Bethesda, MA, 1970.
[4.8] Moisseenko VV, Waker AJ, Hamm RN, and Prestwich WV, Calculation of radiation- induced DNA damage from photons and tritium beta-particles Part II: Tritium RBE and damage complexity.
Radiation and Environmental Biophysics
40(1): 33-38, 2001.[4.9] Chen J, Radiation Quality of Tritium.
Radiation Protection Dosimetry
122(1-4): 546-8, 2006.[4.10] Soloviev V, Ilyin LA, Baranov AE et al, In: Medical Management of Radiation Accidents, Second edition (I.A. Gusev, A.K. Guskova
and F.A. Mettler, eds.). CRC Press, Boca Raton) pp. 46 and 158, 2001.
[4.11] Brues AM, Stroud AN, and Rietz L, Toxicity of tritium oxide to mice. Proceedings for the Society of Experimental Biology and Medicine 79(1): 174-6, 1952.
[4.12] Yokoro K, Yamamoto O, Seyama T, and Kinomura A, Acute and Chronic Effects of Tritiated Water in Mice with Special Reference to its Carcinogenicity: An Interim Report. Radiation Protection Dosimetry 16:165-168, 1986.
[4.13] Yamamoto O, Yokoro T, Seyama A, and Kinomura T, HTO Oral Administration in Mice. I: Threshold Dose Rate for Haematopoietic Death. International Journal of Radiation Biology 57(3): 543-549, 1990.
[4.14] Brenner DJ, Doll R, Goodhead DT, Hall EJ, Land CE, Little JB, Lubin JH, Preston DL, Preston RJ, Puskin JR, Ron E, Sachs RK, Samet JM, Setlow, RB, and Zaider M, Cancer risks attributable to low doses of ionizing radiation: Assessing what we really know.
Proceedings of the National Academy of Science of the United States of America 100 13761-6, 2003.
[4.15] Brown RM, The measurement of tritium in Canadian food items.
Atomic Energy Control Board (now the Canadian Nuclear Safety Commission) AECB INFO 0499, 1995.
[4.16] International Commission on Radiological Protection (ICRP), A Compilation of the Major Concepts and Quantities in Use by the ICRP, ICRP Publication 42, Annals of the ICRP, Vol.14(4), Pergamon Press, New York, N.Y., 1984.
[4.17] National Research Council (NRC), Health Risks from Exposure to Low Levels of Ionizing Radiation. The Committee on the Biological Effects of Ionizing Radiations BEIR V. Washington, DC: National Academies Press, 1990.
[4.18] United Nations Scientific Committee on the effects of ionising radiation (UNSCEAR), Ionising Radiation: Sources and Biological Effects. Vienna, 1982.
[4.19] Yamamoto O, Seyama T, Itoh H, and Fujimoto N, Oral administration of tritiated water (HTO) in mouse. III: Low dose-rate irradiation and threshold dose-rate for radiation risk.
International Journal of Radiation Biology 73(5): 535-541, 1998.
[4.20] Johnson JR, Myers DK, Jackson JS, Dunford DW, Gragtmans NJ, Wyatt HM, Jones AR, and Percy DH, Relative biological effectiveness of tritium for induction of myeloid leukemia in CBA/H mice. Radiation Research 144(1): 82-89, 1995.
[4.21] Straume T, Tritium Risk Assessment. Health Physics 65(6):
673-682, 1993.
[4.22] Diabaté S and Strack S, Organically bound tritium. Health Physics 65(6): 698-712, 1993.
[4.23] Lambert BE, Cytological damage produced in the mouse testes by tritiated thymidine, tritiated water and X-rays. Health Physics 17:
547-557, 1969.
[4.24] Kacena V, Chemical effects of decay of incorporated radioisotopes.
In Proceedings: Conference on Biological Effects of Transmutation and Decay of Incorporated Radioisotopes. Vienna, IAEA, 199-214, 1967.
[4.25] Myers DK, and Johnson JR, Toxicity and dosimetry of tritium: a review. Ottawa, ON: Atomic energy Control Board; Advisory Committee on Radiological Protection; INFO-0377, 1991.
[4.26] Carsten AL, Tritium in the Environment: Isotopic Effects and Transmutation. In Advances in Radiation Biology (John T Lett and Howard Adler, eds). New York, Academic Press, 1979.
[4.27] Feinendegen LE and Bond VP, Transmutation versus beta irradiation in the pathological effects of tritium decay. In Tritium
(AA Moghissi and MW Carter, eds). Nevada, Messenger Graphics, pp. 221-32, 1971.
[4.28] The Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP, 37(2-4):
p. 1-332, 2007.
[4.29] Kotaro Ozasa et al. Studies of the Mortality of Atomic Bomb Survivors, Report 14, 1950–003: An Overview of Cancer and Noncancer Diseases. Radiation Research, 2012. 177(3): p. 229-243.
[4.30] Cardis, E et al. Risk of cancer after low doses of ionising radiation:
retrospective cohort study in 15 countries. BMJ 2005;331:77-80 [4.31] S. Akiba. Cancer risk in high background areas in China and India.
Proceedings of IRPA 10, held in Hiroshima, 14-19, May 2000.
[4.32] Nair RR et al. Background radiation and cancer incidence in Kerala, India-Karanagappally cohort study. Health Phys ;96(1): p. 55-66, Jan. 2009.
[4.33] Carpenter LM, Higgins D, Douglas AJ, Maconochie NES, Omar RZ, Fraser P, Beral V, and Smith PG, Cancer mortality in relation to monitoring for radionuclide exposure in three UK nuclear industry workforces.
British J ournal of Cancer
78: 1224-1232, 1998.[4.34] Fraser P, Carpenter L, Moconochie N, Higgins C, Booth M and Beral V, Cancer mortality and morbidity in employees of the United Kingdom Atomic Energy Authority, 1946-86. British Journal of Cancer 67: 615-24, 1993.
[4.35] Atkinson WD, Law DV, Bromley KJ, and Inskip HM, Mortality of employees of the United Kingdom Atomic Energy Authority, 1946-97. Occupational and Environmental Medicine 61: 577-585, 2004.
[4.36] McGeoghegan D and Binks K, The mortality and cancer morbidity experience of workers at the Capenhurst uranium enrichment facility, 1946-95.
Journal of Radiological Protection
20: 381-401,2000.
[4.37] McGeoghegan D and Binks K, The mortality and cancer morbidity experience of employees at the Chapelcross plant of British Nuclear Fuels plc, 1955-95.
Journal of Radiological Protection
21: 221-250, 2001.[4.38] Cragle DL, McLain RW, Qualters JR, Hickey JLS, Wilkinson GS, Tankersley WG, and Lushbaugh CC, Mortality among workers at a nuclear fuels production facility.
American Journal of Industrial Medicine
14: 379-401, 1988.[4.39] Howe GR, Weeks JL, Miller AB, Chiarelli AM and Etizadi-Amoli J, A study of the health of the employees of Atomic Energy of Canada Limited IV. Analysis of mortality during the period 1950-1981. AECL-9442,1987.
[4.40] Gribbin MA, Weeks JL, and Howe GR, Cancer mortality (1956-1985) among male employees of Atomic Energy of Canada Limited with respect to occupational exposure to external low-linear-energy-transfer ionizing radiation. Radiation Research 133(3):375-80 1993.
[4.41] Zablotska LB, Ashmore JP, and Howe GR, Analysis of mortality among Canadian Nuclear Power Industry Workers after chronic low-dose exposure to ionizing radiation. Radiation Research 161:
633-641, 2004.
[4.42] McGeoghegan D, Binks K, The mortality and cancer morbidity experience of workers at the Capenhurst uranium enrichment facility, 1946-95.
Journal of Radiological Protection
20: 381-401, 2000.[4.43] McGeoghegan D, Gillies M., Riddell AE, and Binks K, Mortality and cancer morbidity experience of female workers at the British Nuclear Fuels Sellafield plant, 1946-1998.
American J ournal of
Industrial Medicine
44: 653-663, 2003.[4.44] Cragle DL, McLain RW, Qualters JR, Hickey JLS, Wilkinson GS, Tankersley WG, and Lushbaugh CC, Mortality among workers at a nuclear fuels production facility. American Journal of Industrial Medicine 14: 379 401, 1988.
[4.45] Cragle DL, Watkins JP, and Robertson-DeMers K, Mortality among workers at the Savannah River nuclear fuels production facility.
ASA 1998 proceedings of the section on statistics in epidemiology.
Alexandria, VA American Statistical Association, pp 83-87, 1998.
[4.46] Schubauer-Berrigan MK, Daniels RD, Fleming DA, Markey AM, Couch JR, Ahrenholz SH, Burphy JS, Anderson JL, and Tseng C-Y, Risk of chronic myeloid and acute leukemia mortality after exposure to ionizing radiation among workers at four U.S. nuclear weapons facilities and a nuclear naval shipyard.
Radiation Research
167: 222-232, 2007.[4.47] Howe GR, Weeks JL, Miller AB, Chiarelli AM and Etizadi-Amoli J, A study of the health of the employees of Atomic Energy of Canada Limited IV. Analysis of mortality during the period 1950-1981. AECL-9442, 1987.
[4.48] Gribbin MA, Weeks JL, and Howe GR, Cancer mortality (1956-1985) among male employees of Atomic Energy of Canada Limited with respect to occupational exposure to external low-linear-energy-transfer ionizing radiation. Radiation Research 133(3):375-80, 1993.
[4.49] Hazelton WD, Suresh MH, Curtis SB, Zielinski JM, Ashmore PJ, and Krewski D, Biologically based analysis of lung cancer incidence in a large Canadian occupational cohort with low-dose ionizing radiation exposure, and comparison with Japanese a-bomb survivors. Journal of Toxicology and Environmental Health (Part A) 69:1013-1038, 2006.
[4.50] Beral V, Inskip H, Fraser P, Booth M, Coleman D, and Rose G,
Mortality of employees of the United Kingdom Atomic Energy Authority, 1946-1979.
British Medical Journal
291: 440-447, 1985.[4.51] Rooney C, Beral V, Maconochie N, Fraser P, and Davies G, Case-control study of prostatic cancer in employees of the United Kingdom Atomic Energy Authority.
British Medical Journal
307:1391-1397, 1993.
[4.52] Atkinson WD, Law DV and Bromley KJ A decline in the mortality from prostate cancer in the UKAEA workforce, In:
Proceedings of the 4th International Conference on Health Effects of Low-level Radiation, September 2002, Oxford. Thomas Telford, London, Paper 08, 2002.
[4.53] Beral V, Fraser P, Carpenter L, Booth M, Brown A, and Rose G, Mortality of employees of the Atomic Weapons Establishment, 1951-82.
British Medical Journal
297: 757-770, 1988.[4.54] Atkinson WD, Law DV, and Bromley KJ, A decline in mortality from prostate cancer in the UK Atomic Energy Authority workforce. Journal of Radiological Protection 27(4): 437-45, 2007.
[4.55] United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), United Nations. Effects of Ionizing Radiation. 2006 Report to the General Assembly, with scientific annexes. United Nations, New York, 2008.
[4.56] Omar RZ, Barber JA, and Smith PG, Cancer mortality and morbidity among plutonium workers at the Sellafield plant of British Nuclear Fuels. British Journal of Cancer 79: 1288-1301, 1999.
[4.57] Johnson P, Atkinson WD, and Nicholls JL, Updated analysis of mortality in workers at UK atomic weapons establishments.
Proceedings of the SRP Sixth International Symposium:
Achievements & Challenges: Advancing Radiation Protection into the 21st Century,1999.
[4.58] Ashmore JP, Gentner NE, and Osborne RV, Analysis of the
results for the AECL cohort in the IARC study on the radiogenic cancer risk among nuclear industry workers in fifteen countries.
Prepared for Atomic Energy of Canada Limited, Chalk River Laboratories, Chalk River, Ontario, 2007.
[4.59] Canadian Nuclear Safety Commission Health Effects, Dosimetry and Radiological Protection of Tritium, 2010.